Explore the words cloud of the H2020MM04 project. It provides you a very rough idea of what is the project "H2020MM04" about.
The following table provides information about the project.
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
|Coordinator Country||Netherlands [NL]|
|Total cost||5˙782˙965 €|
|EC max contribution||5˙782˙965 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM||NL (ROTTERDAM)||coordinator||2˙375˙146.00|
|2||UNIVERSITA POLITECNICA DELLE MARCHE||IT (ANCONA)||participant||669˙452.00|
|3||STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS||NL (AMSTERDAM)||participant||669˙451.00|
|4||UNIVERSITY OF LEICESTER||UK (LEICESTER)||participant||669˙215.00|
|5||UNIVERSITAIR ZIEKENHUIS ANTWERPEN||BE (EDEGEM)||participant||668˙874.00|
|6||CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE||FR (LILLE)||participant||659˙822.00|
|7||AMPHERA BV||NL (DEN BOSCH)||participant||48˙000.00|
|8||EUROPEAN CANCER PATIENT COALITION||BE (BRUXELLES)||participant||23˙000.00|
Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.
Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).
The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).
The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).
The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "H2020MM04" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "H2020MM04" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More